J. Maertens, O. Marchetti, R. Herbrecht, O. Cornely, U. Flückiger et al., European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3???2009 Update, Bone Marrow Transplantation, vol.96, issue.5, pp.709-727, 2011.
DOI : 10.1086/520980

I. Center, M. Blood, and . Research, National Marrow Donor Program (NMDP) European Blood and Marrow Transplant Group (EBMT) American Society of Blood and Marrow Transplantation (ASBMT), Canadian Blood and Marrow Transplant Group (CBMTG), Infectious Disease Society of America (IDSA), et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective, Bone Marrow Transplant, vol.44, pp.453-558, 2009.

D. Andes, Optimizing antifungal choice and administration, Current Medical Research and Opinion, vol.29, issue.sup4, pp.13-21, 2013.
DOI : 10.1185/03007995.2012.761135

M. Pfaller, S. Messer, L. Boyken, S. Tendolkar, R. Hollis et al., Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002, Journal of Clinical Microbiology, vol.42, issue.7, pp.3142-3148, 2001.
DOI : 10.1128/JCM.42.7.3142-3146.2004

H. Tsai, M. Bard, K. Izumikawa, A. Krol, A. Sturm et al., Candida glabrata erg1 Mutant with Increased Sensitivity to Azoles and to Low Oxygen Tension, Antimicrobial Agents and Chemotherapy, vol.48, issue.7, pp.2483-2492, 2004.
DOI : 10.1128/AAC.48.7.2483-2489.2004

M. Ethier, M. Science, J. Beyene, M. Briel, T. Lehrnbecher et al., Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials, British Journal of Cancer, vol.138, issue.10, pp.1626-1663, 2012.
DOI : 10.1038/sj.bmt.1702233

V. Petraitis, R. Petraitiene, A. Groll, K. Roussillon, M. Hemmings et al., Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits, Antimicrobial Agents and Chemotherapy, vol.46, issue.6, pp.1857-69, 2002.
DOI : 10.1128/AAC.46.6.1857-1869.2002

T. Walsh, Echinocandins ??? An Advance in the Primary Treatment of Invasive Candidiasis, New England Journal of Medicine, vol.347, issue.25, pp.2070-2072, 2002.
DOI : 10.1056/NEJMe020142

T. Niwa, T. Shiraga, and A. Takagi, Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes, Biological & Pharmaceutical Bulletin, vol.28, issue.9, pp.1805-1813, 2005.
DOI : 10.1248/bpb.28.1805

S. Ascioglu, J. Rex, B. De-pauw, J. Bennett, J. Bille et al., Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus, Clinical Infectious Diseases, vol.34, issue.1, pp.7-14, 2002.
DOI : 10.1086/323335

C. Girmenia, A. Micozzi, A. Piciocchi, G. Gentile, D. Caprio et al., Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia, Leukemia Research, vol.38, issue.4, pp.469-74, 2014.
DOI : 10.1016/j.leukres.2014.01.007

D. Nachbaur, O. Angelova, D. Orth-höller, A. Ditlbacher, M. Lackner et al., Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study, European Journal of Haematology, vol.55, issue.3, p.261, 2014.
DOI : 10.1111/ejh.12426

C. Cattaneo, S. Monte, A. Algarotti, E. Audisio, E. Borlenghi et al., A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study), Journal of Antimicrobial Chemotherapy, vol.66, issue.9, pp.2140-2145, 2011.
DOI : 10.1093/jac/dkr271

G. Mattiuzzi, G. Alvarado, F. Giles, L. Ostrosky-zeichner, J. Cortes et al., Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies, Antimicrobial Agents and Chemotherapy, vol.50, issue.1, pp.143-150, 2006.
DOI : 10.1128/AAC.50.1.143-147.2006

O. Cornely, J. Maertens, D. Winston, J. Perfect, A. Ullmann et al., Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia, New England Journal of Medicine, vol.356, issue.4, pp.348-59, 2007.
DOI : 10.1056/NEJMoa061094

P. Desplanques, R. Burlacu, V. Poinsignon, H. Boussion, I. Borget et al., Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia, M??decine et Maladies Infectieuses, vol.44, issue.4, pp.174-183, 2014.
DOI : 10.1016/j.medmal.2014.02.005